PA
KROS icon

Profund Advisors’s Keros Therapeutics KROS Stock Holding History

Profund Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,483
Closed -$234K – 1203
2025
Q4 		$234K Buy
+11,483
New +$201K 0.01% 1065
2025
Q3 		– Sell
-11,421
Closed -$152K – 1072
2025
Q2 		$152K Sell
11,421
-148
-1% -$2K 0.01% 939
2025
Q1 		$118K Buy
+11,569
New +$134K 0.01% 938
2024
Q4 		– Sell
-8,392
Closed -$487K – 1156
2024
Q3 		$487K Sell
8,392
-2,415
-22% -$119K 0.02% 545
2024
Q2 		$494K Sell
10,807
-7,854
-42% -$422K 0.02% 500
2024
Q1 		$1.24M Buy
18,661
+7,814
+72% +$463K 0.05% 303
2023
Q4 		$431K Buy
10,847
+826
+8% +$25.9K 0.02% 592
2023
Q3 		$319K Sell
10,021
-2,914
-23% -$109K 0.02% 641
2023
Q2 		$520K Buy
12,935
+1,091
+9% +$47.8K 0.03% 501
2023
Q1 		$506K Buy
+11,844
New +$598K 0.03% 498

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Profund Advisors's KROS Position: Q1 2026 in Review

Profund Advisors sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 11,483 shares — an estimated $234K sold.

Profund Advisors first reported a position in KROS in Q1 2023 and held it in 10 quarters. The position peaked at $1.24M in Q1 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Profund Advisors reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Profund Advisors sold 11,483 Keros Therapeutics shares in Q1 2026, an estimated $234K.
  • Profund Advisors first reported a position in Keros Therapeutics in Q1 2023 and held it in 10 quarters.
  • Profund Advisors's Keros Therapeutics position peaked at $1.24M in Q1 2024.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.